FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912276124> ?p ?o ?g. }

• W2912276124 abstract "Background: Although immunotherapy has emerged as the ‘next generation’ of cancer treatments, it has not yet been shown to be successful in the treatment of patients with prostate cancer, for whom therapeutic options remain limited to radiotherapy and androgen (hormone) deprivation therapy. Previous studies have shown that priming natural killer (NK) cells isolated from healthy individuals via co-incubation with CTV-1 cells derived from an acute lymphoblastic leukaemia (ALL) enhances their cytotoxicity against human DU145 (metastatic) prostate cancer cells, but it remains unknown to what extent NK cells from patients with prostate cancer can be triggered to kill. Herein, we explore the phenotype of peripheral blood NK cells in patients with prostate cancer and compare the capacity of CTV-1 cell-mediated priming and IL-2 stimulation to trigger NK cell-mediated killing of the human PC3 (metastatic) prostate cancer cell line. Methods: The phenotype of resting, primed (co-incubation with CTV-1 cells for 17hrs) and IL-2 activated (100 IU/ml IL-2 for 17hrs) NK cells isolated from frozen-thawed peripheral blood mononuclear cell (PBMC) preparations from patients with prostate cancer (n=24) and their cytotoxicity against PC3 and K562 cells was determined by flow cytometry. Relationship(s) between NK cell phenotypic features and cytotoxic potential were interrogated using Spearman Rank correlation matrices. Results and conclusions: NK cell priming and IL-2 activation of patient-derived NK cells resulted in similar levels of cytotoxicity, but distinct NK cell phenotypes. Importantly, the capacity of priming and IL-2 stimulation to trigger cytotoxicity was patient-dependent and mutually exclusive, in that NK cells from ~50% of patients preferentially responded to priming whereas NK cells from the remaining patients preferentially responded to cytokine stimulation. In addition to providing more insight into the biology of primed and cytokine-stimulated NK cells, this study supports the use of autologous NK cell-based immunotherapies for the treatment of prostate cancer. However, our findings also indicate that patients will need to be stratified according to their potential responsiveness to individual therapeutic approaches." @default.
• W2912276124 created "2019-02-21" @default.
• W2912276124 creator A5001870714 @default.
• W2912276124 creator A5003287905 @default.
• W2912276124 creator A5057129908 @default.
• W2912276124 creator A5067144537 @default.
• W2912276124 creator A5070586395 @default.
• W2912276124 creator A5073567520 @default.
• W2912276124 creator A5088555536 @default.
• W2912276124 date "2019-01-25" @default.
• W2912276124 modified "2023-10-09" @default.
• W2912276124 title "Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation" @default.
• W2912276124 cites W1532988370 @default.
• W2912276124 cites W1541265927 @default.
• W2912276124 cites W1556867369 @default.
• W2912276124 cites W1647534619 @default.
• W2912276124 cites W1671560425 @default.
• W2912276124 cites W1757407923 @default.
• W2912276124 cites W1861152060 @default.
• W2912276124 cites W1965972269 @default.
• W2912276124 cites W1969021168 @default.
• W2912276124 cites W1979811833 @default.
• W2912276124 cites W1981352048 @default.
• W2912276124 cites W2002634103 @default.
• W2912276124 cites W2013473454 @default.
• W2912276124 cites W2013810799 @default.
• W2912276124 cites W2017678578 @default.
• W2912276124 cites W2022069273 @default.
• W2912276124 cites W2027599361 @default.
• W2912276124 cites W2030669661 @default.
• W2912276124 cites W2033107431 @default.
• W2912276124 cites W2044688242 @default.
• W2912276124 cites W2070198752 @default.
• W2912276124 cites W2071065868 @default.
• W2912276124 cites W2078577999 @default.
• W2912276124 cites W2083047945 @default.
• W2912276124 cites W2099126386 @default.
• W2912276124 cites W2103959341 @default.
• W2912276124 cites W2104578054 @default.
• W2912276124 cites W2105057287 @default.
• W2912276124 cites W2105982578 @default.
• W2912276124 cites W2117792530 @default.
• W2912276124 cites W2130513535 @default.
• W2912276124 cites W2141436376 @default.
• W2912276124 cites W2147915788 @default.
• W2912276124 cites W2162377851 @default.
• W2912276124 cites W2222086386 @default.
• W2912276124 cites W2321746654 @default.
• W2912276124 cites W2336971771 @default.
• W2912276124 cites W2345150610 @default.
• W2912276124 cites W2345568581 @default.
• W2912276124 cites W2552724266 @default.
• W2912276124 cites W2581972122 @default.
• W2912276124 cites W2758987079 @default.
• W2912276124 cites W2765888877 @default.
• W2912276124 cites W2788861740 @default.
• W2912276124 cites W2795056814 @default.
• W2912276124 cites W2808851949 @default.
• W2912276124 cites W4214648400 @default.
• W2912276124 doi "https://doi.org/10.3389/fimmu.2018.03169" @default.
• W2912276124 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6362408" @default.
• W2912276124 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30761160" @default.
• W2912276124 hasPublicationYear "2019" @default.
• W2912276124 type Work @default.
• W2912276124 sameAs 2912276124 @default.
• W2912276124 citedByCount "14" @default.
• W2912276124 countsByYear W29122761242019 @default.
• W2912276124 countsByYear W29122761242020 @default.
• W2912276124 countsByYear W29122761242021 @default.
• W2912276124 countsByYear W29122761242022 @default.
• W2912276124 countsByYear W29122761242023 @default.
• W2912276124 crossrefType "journal-article" @default.
• W2912276124 hasAuthorship W2912276124A5001870714 @default.
• W2912276124 hasAuthorship W2912276124A5003287905 @default.
• W2912276124 hasAuthorship W2912276124A5057129908 @default.
• W2912276124 hasAuthorship W2912276124A5067144537 @default.
• W2912276124 hasAuthorship W2912276124A5070586395 @default.
• W2912276124 hasAuthorship W2912276124A5073567520 @default.
• W2912276124 hasAuthorship W2912276124A5088555536 @default.
• W2912276124 hasBestOaLocation W29122761241 @default.
• W2912276124 hasConcept C100701293 @default.
• W2912276124 hasConcept C109316439 @default.
• W2912276124 hasConcept C121608353 @default.
• W2912276124 hasConcept C126322002 @default.
• W2912276124 hasConcept C129374314 @default.
• W2912276124 hasConcept C137061746 @default.
• W2912276124 hasConcept C154317977 @default.
• W2912276124 hasConcept C202751555 @default.
• W2912276124 hasConcept C203014093 @default.
• W2912276124 hasConcept C2776090121 @default.
• W2912276124 hasConcept C2776235491 @default.
• W2912276124 hasConcept C2776438761 @default.
• W2912276124 hasConcept C2777701055 @default.
• W2912276124 hasConcept C2778102761 @default.
• W2912276124 hasConcept C2779723316 @default.
• W2912276124 hasConcept C2780192828 @default.
• W2912276124 hasConcept C28651165 @default.
• W2912276124 hasConcept C502942594 @default.
• W2912276124 hasConcept C55493867 @default.
• W2912276124 hasConcept C59822182 @default.

• next